Noxopharm Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Stock Symbol
  • NOX

Stock Symbol

  • Share Price
  • $0.02
  • (As of Thursday Closing)

Noxopharm General Information

Description

Noxopharm Ltd is an Australian clinical trial preparation and drug development, focused on discovering and developing novel treatments for inflammation, autoimmune diseases and cancer, as well as improving mRNA vaccines. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.

Contact Information

Website
www.noxopharm.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 159 Ridgecrop Drive
  • Suite 71
  • Castle Hill, New South Wales 2154
  • Australia
+61 (02)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
ASX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 159 Ridgecrop Drive
  • Suite 71
  • Castle Hill, New South Wales 2154
  • Australia
+61 (02)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Noxopharm Stock Performance

As of 12-Nov-2026, Noxopharm’s stock price is $0.02. Its current market cap is $8M with 334M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.02 - $0.08 $8M 334M 155K

Noxopharm Financials Summary

As of 30-Sep-2026, Noxopharm has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 15,659 20,609 7,578 9,396
EBITDA (2,247) (2,839) (2,328)
Net Income (3,019) (3,160) (2,345)
Total Assets 1,264 2,993 4,534
Total Debt 3,147 1,619 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Noxopharm Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Noxopharm‘s full profile, request access.

Request a free trial

Noxopharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Noxopharm Ltd is an Australian clinical trial preparation and drug development, focused on discovering and developing no
Biotechnology
Castle Hill, Australia

Saint-Julien- en-Genevois, France
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Noxopharm Competitors (63)

One of Noxopharm’s 63 competitors is Calliditas Therapeutics France, a Corporate Backed or Acquired company based in Saint-Julien- en-Genevois, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Calliditas Therapeutics France Corporate Backed or Acquired Saint-Julien- en-Genevois, France
Moderna Formerly VC-backed Cambridge, MA
BioCryst Pharmaceuticals Corporation Durham, NC
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Spero Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 63 competitors. Get the full list »

Noxopharm Patents

  • 69

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Noxopharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022902590-A0 Functionalised benzopyran compounds and uses thereof Pending 08-Sep-2022
AU-2022902591-A0 Methods of treating fibrosis using functionalised benzopyran compounds Pending 08-Sep-2022
AU-2022901574-A0 Functionalised benzopyran compounds and uses thereof Pending 08-Jun-2022
WO-2023235929-A1 Functionalised benzopyran compounds and uses thereof Inactive 08-Jun-2022
AU-2022900183-A0 Inhibitors of tbk1 and/or ikke Pending 01-Feb-2022
To view Noxopharm’s complete patent history, request access »

Noxopharm Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Noxopharm‘s full profile, request access.

Request a free trial

Ready to get started?

Request a free trial

Noxopharm ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Noxopharm’s complete esg history, request access »

Noxopharm FAQs

  • When was Noxopharm founded?

    Noxopharm was founded in 2015.

  • Where is Noxopharm headquartered?

    Noxopharm is headquartered in Castle Hill, Australia.

  • What industry is Noxopharm in?

    Noxopharm’s primary industry is Biotechnology.

  • Is Noxopharm a private or public company?

    Noxopharm is a Public company.

  • What is Noxopharm’s stock symbol?

    The ticker symbol for Noxopharm is NOX.

  • What is the current stock price of Noxopharm?

    As of 12-Nov-2026 the stock price of Noxopharm is $0.02.

  • What is the current market cap of Noxopharm?

    The current market capitalization of Noxopharm is $8M.

  • Who are Noxopharm’s competitors?

    Calliditas Therapeutics France, Moderna, BioCryst Pharmaceuticals, Alaunos Therapeutics, and Spero Therapeutics are some of the 63 competitors of Noxopharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process